Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) was the target of a significant increase in short interest in September. As of September 30th, there was short interest totalling 45,500 shares, an increase of 27.8% from the August 30th total of 35,600 shares. Currently, 1.9% of the shares of the stock are sold short. Based on an average daily volume of 18,700 shares, the short-interest ratio is presently 2.4 days.
ETTX traded down $0.02 during midday trading on Friday, hitting $5.85. 8,623 shares of the company traded hands, compared to its average volume of 29,386. The company has a debt-to-equity ratio of 0.03, a quick ratio of 9.11 and a current ratio of 9.11. Entasis Therapeutics has a 52-week low of $3.97 and a 52-week high of $9.25. The business has a 50 day simple moving average of $6.56 and a two-hundred day simple moving average of $6.53.
Entasis Therapeutics (NASDAQ:ETTX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.44). Equities analysts anticipate that Entasis Therapeutics will post -4.03 earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Entasis Therapeutics stock. Janney Montgomery Scott LLC raised its stake in shares of Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) by 5.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,917 shares of the company’s stock after purchasing an additional 2,125 shares during the period. Janney Montgomery Scott LLC owned 0.34% of Entasis Therapeutics worth $290,000 at the end of the most recent quarter. 64.99% of the stock is owned by institutional investors and hedge funds.
Several equities analysts have issued reports on ETTX shares. HC Wainwright started coverage on shares of Entasis Therapeutics in a report on Monday, August 19th. They set a “buy” rating and a $18.00 price objective on the stock. Zacks Investment Research raised shares of Entasis Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, October 7th. Finally, ValuEngine raised shares of Entasis Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Entasis Therapeutics presently has a consensus rating of “Buy” and an average target price of $16.75.
About Entasis Therapeutics
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
Read More: Google Finance
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.